Clinical Trial

A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The objective of this Phase 2, open-label, single group, one-time, fixed-dose study is to assess the safety and efficacy of bilateral intraputaminal infusion of AB-1005 (AAV2-GDNF gene therapy) in Japanese patients with moderate Parkinson's Disease (PD).
Protocol Amendment History 2 changes
notable Primary completion pushed: 2028-12-15 -> 2029-06-15 2026-07-30
minor Completion pushed: 2032-06-15 -> 2032-12-15 2026-07-30
Trial Details
NCT Number NCT07566429
Lead Sponsor Bayer
Collaborators: AskBio Inc
Conditions Parkinson Disease
Enrollment 8 participants
Start Date 2027-01-25
Primary Completion 2029-06-15 (estimated)
Study Completion 2032-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-29